Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 16/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.55 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.55 |
| ▸ | CYP8B1 | Q9UNU6 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.44 |
| ▸ | FYN | P06241 | 2/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pramiconazole SCHEMBL3048307 | 1.00 | CYP3A4 (0.55) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| Pramiconazole SCHEMBL6152243 | 0.99 | CYP3A4 (0.55) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| Pramiconazole SCHEMBL6152244 | 0.99 | CYP3A4 (0.55) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL6151936 | 0.94 | CYP3A4 (0.56) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL6151935 | 0.94 | CYP3A4 (0.56) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL17832624 | 0.90 | CYP3A4 (0.43) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL17824324 | 0.90 | CYP3A4 (0.43) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL19730470 | 0.90 | CYP3A4 (0.43) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL29726392 | 0.90 | CYP3A4 (0.51) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL9254879 | 0.90 | CYP3A4 (0.54) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220260565-A1 | METHODS OF TREATING AND DIAGNOSING INFLAMMATORY BOWEL DISEASE | CEDARS-SINAI MEDICAL CENTER (US) | 2022-08-18 | — | — | US | claimed |
| WO-2001001955-A1 | NASAL FORMULATION OF AN ANTIFUNGAL | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-11 | — | — | WO | claimed |
| US-20260083668-A1 | ORALLY ADMINISTERED CORTICOSTEROID COMPOSITIONS | ELLODI PHARMACEUTICALS L P (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260083754-A1 | CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITIS | ELLODI PHARMACEUTICALS, L.P. | 2026-03-26 | — | — | US | disclosed |
| US-12540358-B2 | RNASET2 compositions and methods of treatment therewith | CEDARS-SINAI MEDICAL CENTER (US) | 2026-02-03 | — | — | US | disclosed |
| US-20260027129-A1 | CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITIS | ELLODI PHARMACEUTICALS L P (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260021041-A1 | ORALLY ADMINISTERED CORTICOSTEROID COMPOSITIONS | ELLODI PHARMACEUTICALS L P (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250340627-A1 | METHODS OF SELECTING, BASED ON POLYMORPHISMS, AN INFLAMMATORY BOWEL DISEASE SUBJECT FOR TREATMENT WITH AN ANTI-TL1A ANTIBODY | PROMETHEUS BIOSCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12447157-B2 | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | ELLODI PHARMACEUTICALS, L.P. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12391752-B2 | Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease | PROMETHEUS BIOSCIENCES, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20100222588-A1 | Method for Manufacture of 2-Oxoimidazolidines | THESIS CHEMISTRY, LLC (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222588-A1 | Method for Manufacture of 2-Oxoimidazolidines | THESIS CHEMISTRY, LLC (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2009114080-A2 | PROCESSES FOR PREPARING ENANTIOMERICALLY PURE DIOL AND DIOXOLANE COMPOUNDS | STIEFEL LABORATORIES, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20060078609-A1 | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water soluble and respectively base | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-13 | — | — | US | disclosed |
| EP-1068200-B1 | 2,4,4-TRISUBSTITUTED-1,3-DIOXOLANE ANTIFUNGALS | JANSSEN PHARMACEUTICA NV (BE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004050068-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A BASIC RESPECTIVELY ACIDIC DRUG COMPOUND, A SURFACTANT AND A PHYSIOLOGICALLY TOLERABLE WATER-SOLUBLE ACID RESPECTIVELY BASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-17 | — | — | WO | disclosed |
| EP-0998304-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A BASIC DRUG, A CYCLODEXTRIN, A POLYMER AND AN ACID | JANSSEN PHARMACEUTICA NV (BE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020150616-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLODEXTRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-10-17 | — | — | US | disclosed |
| US-6387906-B1 | DERMATOPHYTES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540358-B2 | RNASET2 compositions and methods of treatment therewith | RNASE1, TRDMT1, RNASEH1 | CYP3A4 3874/4885ABCG2 2535/4885CYP17A1 3923/4885 |
| US-20060078609-A1 | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water soluble and respectively base | SLC10A1, SLC7A1, SLC26A4 | CYP3A4 578/4885ABCG2 13/4885CYP17A1 968/4885 |
| US-20260027129-A1 | CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITIS | IL5, CMA1, CTSD | CYP3A4 177/4885ABCG2 2826/4885CYP17A1 156/4885 |
| US-20250340627-A1 | METHODS OF SELECTING, BASED ON POLYMORPHISMS, AN INFLAMMATORY BOWEL DISEASE SUBJECT FOR TREATMENT WITH AN ANTI-TL1A ANTIBODY | TLL1, TSG101, DNASE1L3 | CYP3A4 4442/4885ABCG2 2920/4885CYP17A1 3473/4885 |
| US-20260021041-A1 | ORALLY ADMINISTERED CORTICOSTEROID COMPOSITIONS | IL17A, CYP4A11, USP7 | CYP3A4 77/4885ABCG2 2682/4885CYP17A1 11/4885 |
| US-12391752-B2 | Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease | DNASE1L3, TLL1, RNASE1 | CYP3A4 4806/4885ABCG2 4336/4885CYP17A1 3624/4885 |
| US-20260083754-A1 | CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITIS | TSLP, CMA1, SI | CYP3A4 836/4885ABCG2 2747/4885CYP17A1 417/4885 |
| US-20100222588-A1 | Method for Manufacture of 2-Oxoimidazolidines | ODC1, CBR3, CBR1 | CYP3A4 35/4885ABCG2 2293/4885CYP17A1 1186/4885 |
| US-20260083668-A1 | ORALLY ADMINISTERED CORTICOSTEROID COMPOSITIONS | IL17A, MUC1, SI | CYP3A4 138/4885ABCG2 2636/4885CYP17A1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.